Abstract
Purpose: Inhibition of COX-2 enzymes is a frequently suggested mechanism for the beneficial effects of NSAIDs on carcinogenesis. The aim of this study was to explore the role of cumulative NSAID use on four common nonskin related cancers and modification by COX-2 G C genotype. Patients and methods: 7621 participants of The Rotterdam Study were included. In a mean follow up period of 10 years, 720 colorectal, lung, breast or prostate cancers occurred. Cumulative NSAID use was calculated per NSAID class. Individual associations of NSAID use and COX-2 G C genotype on cancer risk were explored with Cox proportional hazard models. Next, the association of NSAIDs and cancer stratified by COX-2 genotype was studied. Finally, the effect of combinations of NSAID use and COX-2 genotype on survival times was investigated. Conclusion: Our results confirm the protective effect of NSAID use on colorectal cancer. Individuals diagnosed with colorectal cancer who carry a COX-2 C allele and are on NSAIDs have an increased survival in comparison to non-users with the wild type .
Keywords: Anti-Inflammatory Agents, Non-Steroidal [MeSH], Cohort Study [MeSH], Cyclooxygenase 2 (inhibitors) [MeSH], Neoplasms [MeSH], Polymorphism, Single Nucleotide [MeSH]
Current Cancer Drug Targets
Title: Protective Effect of NSAIDs on Cancer and Influence of COX-2 C G Genotype
Volume: 8 Issue: 8
Author(s): C. Siemes, L. E. Visser, J. W.W. Coebergh, A. Hofman, A. G. Uitterlinden and B.H. Ch. Stricker
Affiliation:
Keywords: Anti-Inflammatory Agents, Non-Steroidal [MeSH], Cohort Study [MeSH], Cyclooxygenase 2 (inhibitors) [MeSH], Neoplasms [MeSH], Polymorphism, Single Nucleotide [MeSH]
Abstract: Purpose: Inhibition of COX-2 enzymes is a frequently suggested mechanism for the beneficial effects of NSAIDs on carcinogenesis. The aim of this study was to explore the role of cumulative NSAID use on four common nonskin related cancers and modification by COX-2 G C genotype. Patients and methods: 7621 participants of The Rotterdam Study were included. In a mean follow up period of 10 years, 720 colorectal, lung, breast or prostate cancers occurred. Cumulative NSAID use was calculated per NSAID class. Individual associations of NSAID use and COX-2 G C genotype on cancer risk were explored with Cox proportional hazard models. Next, the association of NSAIDs and cancer stratified by COX-2 genotype was studied. Finally, the effect of combinations of NSAID use and COX-2 genotype on survival times was investigated. Conclusion: Our results confirm the protective effect of NSAID use on colorectal cancer. Individuals diagnosed with colorectal cancer who carry a COX-2 C allele and are on NSAIDs have an increased survival in comparison to non-users with the wild type .
Export Options
About this article
Cite this article as:
Siemes C., Visser E. L., Coebergh W.W. J., Hofman A., Uitterlinden G. A. and Stricker Ch. B.H., Protective Effect of NSAIDs on Cancer and Influence of COX-2 C G Genotype, Current Cancer Drug Targets 2008; 8 (8) . https://dx.doi.org/10.2174/156800908786733414
DOI https://dx.doi.org/10.2174/156800908786733414 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Metastatic Process: Methodological Advances and Pharmacological Challenges
Current Medicinal Chemistry Identification of a Novel Human Peroxisomal 2,4-Dienoyl-CoA Reductase Related Protein Using the M13 Phage Protein VI Phage Display Technology
Combinatorial Chemistry & High Throughput Screening Epigenetic Therapies and Potential Drugs for Treating Human Cancer
Current Drug Targets Molecular Mechanisms Regulating Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Targeting Prostate Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Sorafenib (BAY 43-9006) in Hepatocellular Carcinoma Patients: From Discovery to Clinical Development
Current Medicinal Chemistry Advances in Chemotherapy and Targeted Systemic Therapies for Urothelial Cancer
Current Drug Therapy Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease
Current Alzheimer Research SOCS6 Functions as a Tumor Suppressor by Inducing Apoptosis and Inhibiting Angiogenesis in Human Prostate Cancer
Current Cancer Drug Targets Small Molecule Toxins Targeting Tumor Receptors
Current Pharmaceutical Design Potential Application of Gene Therapy to X-Linked Agammaglobulinemia
Current Gene Therapy Pathophysiological Role of Hepatocyte Nuclear Factor 6 in Negative Regulation of Hepatic Apoptosis: A Novel Hypothesis
Current Molecular Medicine Molecular Dynamics Simulation and Docking Studies of Selenocyanate Derivatives as Anti-Leishmanial Agents
Combinatorial Chemistry & High Throughput Screening Patent Selections
Recent Patents on Biotechnology Mitochondria and Familial Predisposition to Breast Cancer
Current Genomics Antigen-specific Immunotherapy in Ovarian Cancer and p53 as Tumor Antigen
Current Pharmaceutical Design Recent Advances in Drug Design of Epidermal Growth Factor Receptor Inhibitors
Current Medicinal Chemistry Pleiotropic Effects of Omega-3 Fatty Acids
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Targeting Angiogenesis for Treatment of NSCLC Brain Metastases
Current Cancer Drug Targets Editorial [Hot topic: Angiogenesis and Lymphangiogenesis in Common Diseases (Guest Editor: Y. Cao)]
Current Molecular Medicine